NewsRoom Articles - Page 203 of 222

WednesdayOct 07, 2020 9:30 am

Pioneer Research Unveils Electronic Skin That Can Feel Pain

Researchers from RMIT University in Australia have created an artificial skin that electronically reacts to pain stimuli like human skin. This has paved the way for intelligent robotics and far better prosthetics to be developed as well as the development of alternative skin grafts which are non-invasive. The prototype device imitates the body’s instant feedback response and reacts with the same speed as the nerve signals would when they travel to the human brain. Madhu Bhaskaran, a professor who is also the lead researcher, stated that the prototype was a remarkable advancement towards intelligent robotics and future biomedical technologies. He…

TuesdayOct 06, 2020 1:15 pm

Georgia Scientists Receive Grant to Improve Mood Disorder Treatment Tool

A team of Georgia State scientists has received a two-year grant to further develop a tool to help psychiatrists better diagnose and treat mood disorders. The $875,110 grant was provided by the National Institute of Mental Health and it will fund studies that will make it easier for mental health professionals to quickly diagnose and treat mental health conditions with accuracy. The researchers are based at the Center for the Translational Research in Neuroimaging and Data Science (TReNDS). TReNDS is a tri-institutional effort supported by Georgia State University, Georgia Institute of Technology, and Emory University that is focused on making…

TuesdayOct 06, 2020 12:53 pm

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is “One to Watch”

Processa Pharmaceuticals aims to develop products where existing clinical evidence of efficacy already exists in the targeted unmet medical need condition with the drug itself or a drug with very similar pharmacology The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete Processa’s current development pipeline features multiple clinical drug candidates, given the recent acquisitions of three additional development-focused licensing agreement since June 2020 In total, the company’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and…

TuesdayOct 06, 2020 10:00 am

Fecal Transplants Can Rebalance the Microbiota of Infants Born by C-Section

The human gastrointestinal tract has a diverse population of microorganisms, especially bacteria, fungi, and viruses. These are collectively referred to as the microbiota. Some of these colonies are passed on from mother to child during birth through the vaginal canal. However, babies who are born by cesarean section miss out on this microbiota transfer, and that puts their long-term health at risk since they will be more susceptible to immune-related complications later in life. Now a team of researchers has discovered that a mother’s microbiota can be transferred to an infant after birth through a procedure called fecal microbiota transplantation…

MondayOct 05, 2020 12:52 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Partnership with Imaging Specialists IAG Gives Tech Boost to Upcoming Brain Cancer Drug Trials

Clinical-stage biotech developer CNS Pharmaceuticals is working to demonstrate the potential effectiveness of its novel drug, Berubicin, in treating aggressive and rare brain cancer glioblastoma multiforme (“GBM”) CNS expects to launch Phase II trials of Berubicin later this year or in Q1 of 2021, building on promising results shown in initial trials One patient in the Phase I trial has remained cancer-free over the course of 14 years, and 44 percent of the patients who could be evaluated experienced a clinically significant positive response to Berubicin CNS’s laser-focused strategy for developing a GBM therapy is also leading the company to…

MondayOct 05, 2020 12:00 pm

Laser-Welded Sugar: The New Technique to Repair Damaged Blood Vessels?

A study that was published in the Nature Biomedical Engineering journal by Rice University bioengineers demonstrated how the researchers created blood vessel networks from 3D-printed sugar templates which they used to keep tightly packed cells alive for a 2-week period. Ian Kinstlinger, who is the lead author of the study, said that among the biggest obstacles in developing clinically significant tissues was trying to provide enough nutrients and oxygen to all the millions of living cells in a large tissue structure. He explained that the development of new materials and technologies that mimic vascular networks that occur naturally had significantly…

MondayOct 05, 2020 9:45 am

Some Cerebral Palsy Cases Could Be Due to a Patient’s Genes, Research Finds

In an article that was published in Nature Genetics, scientists have confirmed that almost 14% of all cerebral palsy cases may be connected to an individual’s genes and indicate that those genes control how brain circuits are wired in early development. Cerebral palsy is a brain disorder that affects an individual’s ability to move and maintain posture and balance. It’s a motor disability that is common in childhood. The National Institute of Neurological Disorders was the main funder behind this research. The scientists’ findings were based on the biggest genetic study of cerebral palsy that has ever been conducted. Additionally,…

FridayOct 02, 2020 1:30 pm

New Study Confirms Children Are Significantly Less Likely to Contract Coronavirus

A new study that centered on global coronavirus transmission data discovered that young people and children are about 40% less likely to be infected with COVID-19 as compared to adults when exposed to an individual who has the virus. The study, which was co-led by researchers from University College London and published in JAMA Pediatrics, added more than 13,900 studies to its May pre-print in order to update their meta-analysis and systematic review. The additional studies were used to understand how susceptible children were to the coronavirus and whether they transmitted the infection to others. Professor Russell Viner, who is…

FridayOct 02, 2020 10:42 am

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is “One to Watch”

VistaGen’s product portfolio consists of three novel drug candidates that, together, target multiple anxiety disorders, depression disorders and neurological disorders Two of the company’s drug candidates have received an FDA fast track designation, including for the treatment of social anxiety disorder, major depressive disorder and neuropathic pain. The global CNS therapeutics market is estimated to reach $130 billion by 2025 The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year VistaGen is committed to developing and commercializing multiple new generation medications that go beyond the standard of care…

FridayOct 02, 2020 10:30 am

High Fructose Intake May Worsen Inflammatory Bowel Disease

A new study by the Stony Brook University indicates that fructose consumption may actually aggravate an intestinal inflammation into inflammatory bowel disease. The study, which was led by David Montrose of the Stony Brook University Renaissance School of Medicine, was published in the Cellular and Molecular Gastroenterology and Hepatology online journal. According to the U.S. CDC, roughly three million Americans are diagnosed with Inflammatory Bowel Diseases (“IBD”) each year, which is a one million increase in the number of cases in comparison with cases in the late 90s. The number of IBD cases appears to be increasing globally as well.…